Search clinical trials for: Nimenrix (GSK134612 vaccine)

Total 6167 results

GlaxoSmithKline

Completed

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

Infections, Meningococcal | Meningococcal Vaccines

Germany, France
GlaxoSmithKline

Completed

Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Infections, Meningococcal | Meningococcal Vaccines

India, Lebanon, Philippines, Saudi Arabia
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

Infections, Meningococcal

Germany, Korea, Republic of, Dominican Republic
GlaxoSmithKline

Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

Infections, Meningococcal

United States, Czechia
GlaxoSmithKline

Completed

Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration

Infections, Meningococcal

Taiwan, Mexico
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
Pfizer

Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Infections, Meningococcal

Philippines
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

Infections, Meningococcal

Germany, France
GlaxoSmithKline

Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Infections, Meningococcal

Australia
Public Health England

Completed

Pertussis and Meningitis C Concomitant Vaccination in Adolescents (Mutliboost)

Pertussis | Meningitis | Immunization | Preventive Immunization; Meningitis

United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Infections, Meningococcal

Finland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
GlaxoSmithKline

Completed

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Infections, Meningococcal

Sweden, Denmark
GlaxoSmithKline

Completed

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

Infections, Meningococcal

Taiwan, Philippines, India
Sanofi Pasteur, a Sanofi Company

Recruiting

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Healthy Volunteers | Meningococcal Immunisation

Czechia, Denmark, Finland, Germany, Poland, Romania
GlaxoSmithKline

Completed

Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

Infections, Meningococcal

Germany, Austria, Greece
GlaxoSmithKline

Completed

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Infections, Meningococcal

Philippines, Lebanon
GlaxoSmithKline

Completed

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Infections, Meningococcal

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Pfizer

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Infections, Meningococcal

Australia, Canada, Czechia, Panama, South Africa, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain
GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
GlaxoSmithKline

Completed

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Infections, Streptococcal

Czechia
Pfizer

Completed

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Meningococcal Vaccine

Finland, Spain, Poland
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Virus Diseases | Bacterial Infections | Neisseria Meningitidis

Finland
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Virus Diseases

Mali, Senegal
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission

Breast Cancer
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Meningitis

Mali
Canadian Immunization Research Network
University of British Columbia; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaborators

Completed

Adolescent MenACWY Booster Study

Meningococcal Disease, Invasive

Canada
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
Medical University of South Carolina

Completed

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Aging | HIV Lipodystrophy

United States

3

Subscribe